Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000122 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL354446 | 0.73 | — | — | |
| Valine SCHEMBL4841645 | 0.72 | ALDH1A1 (0.52) | SLC7A5SMN1; SMN2FFAR2NOS1TSHR | |
| Valine SCHEMBL16597296 | 0.71 | SLC7A5 (0.60) | SLC7A5SMN1; SMN2ALDH1A1LMNA | |
| Valine SCHEMBL2032555 | 0.71 | — | — | |
| Valine SCHEMBL2029503 | 0.71 | — | — | |
| Valine SCHEMBL22978644 | 0.71 | SLC7A5 (0.94) | SLC7A5ALDH1A1 | |
| Valine SCHEMBL28314968 | 0.71 | — | — | |
| Valine SCHEMBL28052598 | 0.69 | SLC7A5 (0.88) | SLC7A5LMNA | |
| Valine SCHEMBL4582565 | 0.69 | SLC7A5 (0.88) | SLC7A5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| EP-1740560-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | Prosidion Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103021-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | PROSIDION LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | IAPP, GPR119, CPT1A | SLC7A5 907/4885CSNK2A1 1097/4885SMN1; SMN2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.